Edition:
United States

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

447JPY
28 Apr 2017
Change (% chg)

¥-32 (-6.68%)
Prev Close
¥479
Open
¥485
Day's High
¥496
Day's Low
¥445
Volume
9,035,000
Avg. Vol
6,743,341
52-wk High
¥938
52-wk Low
¥142

Latest Key Developments (Source: Significant Developments)

OFFICIAL-BRIEF-GNI Group to acquire Berkeley Advanced Biomaterials through GNI USA(April 18)
Wednesday, 19 Apr 2017 05:22am EDT 

Corrects target company name in headline and text after GNI Group officially corrects statement:* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterials, Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc..* Says Berkeley Advanced Biomaterials,Inc. will set up a new unit, and transfer all property and business to unit .* Says transaction effective July 31.  Full Article

GNI Group to acquire Berkeley Advanced Biomaterial through GNI USA
Tuesday, 18 Apr 2017 04:41am EDT 

April 18 (Reuters) - GNI Group Ltd <2160.T>:* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterial,Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc..* Says Berkeley Advanced Biomaterial,Inc. will set up a new unit, and transfer all property and business to unit .* Says transaction effective July 31.  Full Article

GNI Group gets approval for clinical trial in China for drug of diabetic nephropathy
Wednesday, 17 Aug 2016 04:16am EDT 

GNI Group Ltd <2160.T>:Says it received approval from China Food and Drug Administration for a pulmonary fibrosis treatment drug's effect on diabetic nephropathy.  Full Article

GNI Group unit gets manufacture and marketing approval of Etuary® in China
Wednesday, 3 Aug 2016 01:46am EDT 

GNI Group Ltd <2160.T>:Says its unit Beijing Continent Pharmaceuticals Co., Ltd. obtained the manufacture and marketing approval of Etuary® for the treatment of idiopathic pulmonary fibrosis in China.  Full Article

GNI Group subsidiary to set up subsidiary
Monday, 28 Mar 2016 03:00am EDT 

GNI Group Ltd:Says subsidiary GNI-EPS (HONG KONG) HOLDINGS LIMITED to set up a subsidiary in Shanghai, named GNI-EPS (SHANGHAI) PHARMACEUTICALS, INC.Says GNI-EPS (SHANGHAI) PHARMACEUTICALS, INC with registered capital of 10 mln yuan.  Full Article

GNI Group applies clinical trial permission in U.S
Sunday, 13 Mar 2016 10:00pm EDT 

GNI Group Ltd:Says applied clinical trial permission in U.S on March 11 to FDA for liver fiber medicine disease treatment F351.  Full Article

GNI Group subsidiary receive subsidy
Tuesday, 24 Nov 2015 05:00am EST 

GNI Group Ltd:Says Beijing-based pharmaceutical subsidiary received subsidy of 788,000 yuan or about 15,188,000 yen for creation of technology.  Full Article

GNI Group raises consolidated full-year revenue outlook for FY 2015
Wednesday, 11 Nov 2015 08:15pm EST 

GNI Group Ltd:Says the company increased the consolidated full-year outlook for revenue to 1,039 mln yen from 864 mln yen, for the fiscal year ending Dec. 31, 2015.Operating profit forecast increased to a loss of 520 mln yen from a loss of 639 mln yen.Sees a decrease of ordinary profit forecast to a loss of 584 mln yen from a loss of 575 mln yen.Sees a decrease of net profit forecast to a loss of 581 mln yen from a loss of 558 mln yen.Sees a decrease of earnings per share to a loss of 5.13 yen from a loss of 4.96 yen.Says revenue outlook raised due to increased sale of product in China and yen devaluation, net profit outlook lowered due to increased non-operating costs.  Full Article

GNI Group commences pilot test for Etuary in China
Friday, 3 Jul 2015 03:00am EDT 

GNI Group Ltd:Says it commences a pilot test for Etuary (medicines for the treatment of Radiation-induced Pneumonitis) in China on July 4.  Full Article

GNI Group announces subsidy of subsidiary
Tuesday, 30 Jun 2015 04:15am EDT 

GNI Group Ltd:Says its Shanghai-based subsidiary received subsidy of 800,000 yuan (about 16,072,000 yen) for the phase II clinical trial for F351 (treatment for liver fibrosis) in China, on June 29.Says the remaining 200,000 yuan (about 4,018,000 yen) will be received by the end of the clinical trial.  Full Article

More From Around the Web

CORRECTED-OFFICIAL-BRIEF-GNI Group to acquire Berkeley Advanced Biomaterials through GNI USA(April 18)

* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterials, Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc.